RARE shares hit all-time low after failed Angelman syndrome trial
Ultragenyx Pharmaceutical (RARE) logged its worst trading day on record and closed at an all-time low Thursday after its Angelman syndrome treatment failed a key trial, triggering Wall Street target cuts and takeover speculation from Martin Shkreli.
Shares of Ultragenyx Pharmaceutical (RARE) suffered their worst trading day on record and closed at an all-time low on Thursday after its Angelman syndrome treatment failed a key trial. The result triggered broad Wall Street target cuts and takeover speculation from former pharma executive Martin Shkreli.